Cell motility as a prognostic factor in stage I nonsmall cell lung carcinoma: The role of gelsolin expression

Cancer

Volumn 85, Issue 1, 1999, Pages 47-57

  Shieh, Dar Bin ^a   Godleski, John ^b   Herndon II, James E ^c   Azuma, Toshifumi ^a   Mercer, Harriet ^a   Sugarbaker, David J ^a   Kwiatkowski, David J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ABP 280; Gelsolin; Nonsmall cell lung carcinoma; Prognostic factors; Rac

Indexed keywords

GELSOLIN; MONOCLONAL ANTIBODY;

ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELL MOTILITY; CLINICAL ARTICLE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN INTERACTION; RECURRENT DISEASE; STATISTICAL ANALYSIS; WORLD HEALTH ORGANIZATION;

CARCINOMA, NON-SMALL-CELL LUNG; CELL MOVEMENT; CONTRACTILE PROTEINS; GELSOLIN; GTP-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICROFILAMENT PROTEINS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PILOT PROJECTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RAC GTP-BINDING PROTEINS;

EID: 0032893518     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990101)85:1<47::AID-CNCR7>3.0.CO;2-L     Document Type: Article

References (61)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Mountain CF. A new international staging system for lung cancer. Chest 1986;89:225S-33S.
3. Bulzebruck H, Bopp R, Drings P, Bauer E, Krysa S, Probst G, et al. New aspects in the staging of lung cancer: prospective validation of the International Union Against Cancer TNM classification. Cancer 1992;70:1102-10.
4. Fry WA, Menck HR, Winchester DP. The National Cancer Data Base report on lung cancer. Cancer 1996;77:1947-55.
5. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB, Lee JS, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 1994;86: 673-80.
6. Rusch VW, Albain KS, Crowley JJ, Rice TW, Lonchyna V, McKenna R Jr., et al. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy: a Southwest Oncology Group trial. J Thorac Cardiovasc Surg 1993;105:97-106.
7. Le Chevalier T, Arriagada R, Tarayre M, Lacombe-Terrier MJ, Laplanche A, Quoix E, et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst 1992;84:58.
8. Le Cesne A, Le Chevalier T, Arriagada R. Impact of chemotherapy on survival in locally advanced non-small cell lung cancer: the Gustave-Roussy experience. Lung Cancer 1995; 12:S79-85.
9. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330: 153-8.
10. Graziano SL. Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer 1997;17:S37-S58.
11. Strauss GM, Kwiatkowski DJ, Harpole DH, Lynch TJ, Skarin AT, Sugarbaker DJ. Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. J Clin Oncol 1995;13:1265-79.
12. Harpole DH, Herndon JE, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995;55:51-6.
13. Harpole DH, Richards WG, Herndon JE, Sugarbaker DJ. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg 1996;61:1470-6.
14. Pastorino U, Andreola S, Tagliabue E, Pezzella F, Incarbone M, Sozzi G, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997;15: 2858-65.
15. Graziano SL, Tatum AH, Newman NB, Oler A, Kohman LJ, Veit LJ, et al. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer. Cancer Res 1994;54:2908-13.
16. Kanters SD, Lammers JW, Voest EE. Molecular and biological factors in the prognosis of non-small cell lung cancer. Eur Respir J 1995;8:1389-97.
17. Macchiarini P, Fontanini G, Hardin MJ, Chuanchieh H, Bigini D, Vignati S, et al. Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer. J Thorac Cardiovasc Surg 1993;106: 80-9.
18. Button E, Shapland C, Lawson D. Actin, its associated proteins and metastasis. Cell Motil Cytoskeleton 1995;30: 247-51.
19. Zetter BR. The cellular basis of site specific tumor metastasis. N Engl J Med 1990;322:605-12.
20. Lester BR, McCarthy JB. Tumor cell adhesion to the extracellular matrix and signal transduction mechanisms implicated in tumor cell motility, invasion and metastasis. Cancer Metastasis Rev 1992;11:31-44.
21. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992;340:1120-4.
22. Macchiarini P, Fontanini G, Hardin MJ. Relation of neovascularisation to metastasis of non-small cell lung cancer. Lancet 1992;340:145-6.
23. Ura H, Bonfil RD, Reich R, Reddel R, Pfeifer A, Harris CC, et al. Expression of type IV collagenase and procollagen genes and its correlation with the tumorigenic, invasive, and metastatic abilities of oncogene-transformed human bronchial epithelial cells. Cancer Res 1989;49:4615-21.
24. Strauli P, Haemmerli G. The role of cancer cell motility in invasion. Cancer Metastasis Rev 1984;3:127-41.
25. Jiang WG. Membrane ruffling of cancer cells: a parameter of tumour cell motility and invasion. Eur J Surg Oncol 1995;21: 307-9.
26. Fridman R, Scott AF, Muller D, Reich R, Penno MB. The role of cell adhesion and migration in the in vitro invasiveness of mouse adrenal carcinoma cells. Invasion Metastasis 1990;10: 208-24.
27. Symons M. Rho family GTPases: the cytoskeleton and beyond. Trends Biochem Sci 1996;21:178-81.
28. Nobes C, Hall A. Regulation and function of the Rho subfamily of small GTPases. Curr Opin Genet Devel 1994;4:77-81.
29. Michiels F, Habets GG, Stam JC, van der Kammen RA, Collard JG. A role for Rac in Tiam1-induced membrane ruffling and invasion. Nature 1995;375:338-40.
30. Qiu RG, Chen J, Kirn D, McCormick F, Symons M. An essential role for Rac in Ras transformation. Nature 1995;374: 457-9.
31. Gorlin JB, Yamin R, Egan S, Steward M, Stossel TP, Kwiatkowski DJ, et al. Human endothelial actin binding protein (ABP-280, non-muscle filamin): a molecular leaf spring. J Cell Biol 1990;111:1089-105.
32. Cunningham CC. Actin structural proteins in cell motility. Cancer Metastasis Rev 1992;11:69-77.
33. Bouffard D, Duncan LM, Howard CA, Mihm MC Jr., Byers HR. Actin-binding protein expression in benign and malignant melanocytic proliferations. Hum Pathol 1994;25:709-14.
34. Kwiatkowski DJ. Predominent induction of gelsolin and actin-binding protein during myeloid differentiation. J Biol Chem 1988;263:13857-62.
35. Yin HL, Stossel TP. Control of cytoplasmic actin gel-sol transformation by gelsolin, a calcium dependent regulatory protein. Nature 1979;281:583.
36. Cunningham CC, Stossel TP, Kwiatkowski DJ. Enhanced motility in NIH 3T3 fibroblasts that overexpress gelsolin. Science 1991;251:1233-6.
37. Azuma T, Witke W, Stossel TP, Hartwig JH, Kwiatkowski DJ. Gelsolin is a downstream effector of rac for fibroblast motility. EMBO J 1998;17:1362-70.
38. Asch HL, Head K, Dong Y, Natoli F, Winston JS, Connolly JL, et al. Widespread loss of gelsolin in breast cancers of humans, mice, and rats. Cancer Res 1996;56:4841-5.
39. Chaponnier C, Gabbiani G. Gelsolin modulation in epithelial and stromal cells of mammary carcinoma. Am J Pathol 1989;134:597-603.
40. Tanaka M, Mullauer L, Ogiso Y, Fujita H, Moriya S, Furuuchi K, et al. Gelsolin: a candidate for suppressor of human bladder cancer. Cancer Res 1995;55:3228-32.
41. Mullauer L, Fujita H, Suzuki H, Katabami M, Hitomi Y, Ogiso Y, et al. Elevated gelsolin and alpha-actin expression in a flat revertant R1 of ha-ras oncogene-transformed Nih/3t3 cells. Biochem Biophys Res Commun 1990;171:852-9.
42. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, et al. Gene expression profiles in normal and cancer cells. Science 1997;276:1268-72.
43. Kwiatkowski DJ, Harpole DH, Godleski J, Herndon JE, Shieh D, Richards W, et al. Molecular-pathologic substaging in 244 stage I non-small cell lung cancer patients: clinical implications. J Clin Oncol 1998;16:2468-77.
44. Kreyberg L. Histological lung cancer types: a morphological and biological correlation. Acta Pathol Microbiol Scand Suppl 1962;157:1-92.
45. Shapiro GI, Park JE, Edwards CD, Mao L, Merlo A, Sidransky D, et al. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res 1995;55: 6200-9.
46. Liota LA, Schiffman E. Tumor motility factors. Cancer Surv 1988;7:631-52.
47. Stossel T. On the crawling of animal cells. Science 1993;260: 1086-94.
48. Lauffenburger D, Horwitz A. Cell migration: a physically integrated molecular process. Cell 1996;84:359-69.
49. Lamb JA, Allen PG, Tuan BY, Janmey PA. Modulation of gelsolin function: activation at low pH overrides Ca2+ requirement. J Biol Chem 1993;268:8999-9004.
50. Janmey P, Stossel T. Modulation of gelsolin function by phosphatidylinositol 4,5-bisphosphate. Nature 1987;325: 362-4.
51. Witke W, Sharpe AH, Hartwig JH, Azuma T, Stossel TP, Kwiatkowski DJ. Hemostatic, inflammatory, and fibroblast responses are blunted in mice lacking gelsolin. Cell 1995;81: 41-51.
52. Kothakota S, Azuma T, Reinhard C, Klippel A, Tang J, Chu K, et al. Caspace-3-generated fragment fo gelsolin: effector of morphological change in apoptosis. Science 1997; 278:294-8.
53. Ohtsu M, Sakai N, Fujita H, Kashiwagi M, Gasa S, Shimizu S, et al. Inhibition of apoptosis by the actin-regulatory protein gelsolin. EMBO J 1997;16:4650-6.
54. Tanaka M, Mullauer L, Ogiso Y, Fujita H, Moriya S, Furuuchi K, et al. Gelsolin: a candidate for suppressor of human bladder cancer. Cancer Res 1995;55:3228-32.
55. Asch HL, Head K, Dong Y, Natoli F, Winston JS, Connolly JL, et al. Widespread loss of gelsolin in breast cancers of hu-mans, mice, and rats. Cancer Res 1996;56:4841-5.
56. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, et al. Gene expression profiles in normal and cancer cells. Science 1997;276:1268-72.
57. Dosaka-Akita H, Hommura F, Fujita H, Kinoshita I, Nishi M, Morikawa T, et al. Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers. Cancer Res 1998;58:322-7.
58. Müllauer L, Fujita H, Ishizaki A, Kuzumaki N. Tumor-suppressive function of mutated gelsolin in ras-transformed cells. Oncogene 1993;8:2531-6.
59. Rodríguez-Fernandez J, Geiger B, Salomon D, Sabanay I, Zöller M, Ben-Ze'ev A. Suppression of tumorigenicity in transformed cells after transfection with vinculin cDNA. J Cell Biol 1992;119:427-38.
60. Glück U, Kwiatkowski D, Ben-Ze'ev A. Suppression of tumorigenicity in simian virus 40-transformed 3T3 cells transfected with a-actinin cDNA. Proc Nat Acad Sci U S A 1993; 90:383-7.
61. Bao L, Loda M, Janmey PA, Stewart R, Anand-Apte B, Zetter BR. Thymosin beta15: a novel regulator of tumor cell motility upregulated in metastatic prostate cancer. Nat Med 1996; 2:1322-8.